Evaluation of Interfraction Setup Uncertainty of Patients With Glioblastoma Wearing TTFields (Tumor Treating Fields) During Radiation Therapy

Pan, Mingyuan; Xiao, Ying; Zhu, L.-Y.; Dong, Shengnan; Liang, Li‐Ping; Sun, Lei; Shi, Wenyin; Wang, Yang

doi:10.1016/j.prro.2023.06.006

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, image‐guided RT (IGRT) is recommended. For patients undergoing non‐IGRT, a PTV dilation boundary of 5 mm is recommended to improve the efficacy of RT because in the plans with 3 mm and 4 mm CTV expansion, the coverage of prescription dose in CTV decreased to 92% 66 . These studies confirm that RT can be delivered with electrode patch preservation after PTV adjustment and scalp protection.…”

Section: Use Of Ttfields To Treat Ndgbm Patients: Present and Futurementioning

confidence: 65%

Theory and application of TTFields in newly diagnosed glioblastoma

Yu,

Zeng,

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

BackgroundGlioblastoma is the most common primary malignant brain tumor in adults. TTFields is a therapy that use intermediate‐frequency and low‐intensity alternating electric fields to treat tumors. For patients with ndGBM, the addition of TTFields after the concurrent chemoradiotherapy phase of the Stupp regimen can improve prognosis. However, TTFields still has the potential to further prolong the survival of ndGBM patients.AimBy summarizing the mechanism and application status of TTFields in the treatment of ndGBM, the application prospect of TTFields in ndbm treatment is prospected.MethodsWe review the recent literature and included 76 articles to summarize the mechanism of TTfields in the treatment of ndGBM. The current clinical application status and potential health benefits of TTFields in the treatment of ndGBM are also discussed.ResultsTTFields can interfere with tumor cell mitosis, lead to tumor cell apoptosis and increased autophagy, hinder DNA damage repair, induce ICD, activate tumor immune microenvironment, reduce cancer cell metastasis and invasion, and increase BBB permeability. TTFields combines with chemoradiotherapy has made progress, its optimal application time is being explored and the problems that need to be considered when retaining the electrode patches for radiotherapy are further discussed. TTFields shows potential in combination with immunotherapy, antimitotic agents, and PARP inhibitors, as well as in patients with subtentorial gliomas.ConclusionThis review summarizes mechanisms of TTFields in the treatment of ndGBM, and describes the current clinical application of TTFields in ndGBM. Through the understanding of its principle and application status, we believe that TTFields still has the potential to further prolong the survival of ndGBM patients. Thus,research is still needed to explore new ways to combine TTFields with other therapies and optimize the use of TTFields to realize its full potential in ndGBM patients.

show abstract

Section: Use Of Ttfields To Treat Ndgbm Patients: Present and Futurementioning

confidence: 65%